Sterne Kessler Building Interior

Chandrika Vira



Chandrika Vira

Chandrika Vira is a director in Sterne Kessler’s Trial & Appellate and Biotechnology & Chemical Practice Groups. Chandrika represents clients in complex patent litigations in federal district courts, in contested proceedings before the Patent Trial and Appeal Board, and before the Federal Circuit on appeal.

Chandrika has litigated cases involving a broad range of technologies in the pharmaceutical, biotechnological arts, and electrical arts. Chandrika focuses her practice on litigating cases involving small-molecule pharmaceuticals under the Hatch-Waxman Act and biologics and biosimilars under the Biologics Price Competition and Innovation Act (BPCIA).

In 2017 and 2018, Chandrika was named a "Rising Star" in Intellectual Property by Super Lawyers.

Prior to law school, Chandrika worked as a consultant for two technology companies where she advised companies on implementing technological solutions. While in law school at The George Washington University, Chandrika participated in the Law Students in Court Clinic where she had the opportunity to represent clients in the Superior Court of the District of Columbia in the Criminal Division. Chandrika received her B.A. in molecular biology from Coe College.

Technical Publications

  • Vira, C. (1998). “Optical and physical properties of bismuth borate glasses related to structure,” Phys. C hem. Glasses, 39(2), 83-6.
  •  Vira, C. (1999). “A Structural analysis of the physical properties of bismuth and lead based glasses.” Phys. C hem. Glasses,40(6), 326-32.


  • DCA Live, "Emerging Women Leaders in Law" (2020)
  • Super Lawyers, "Rising Star - Washington, D.C." (2018-2017)

Representative Matters

  • Genentech, Inc. et al. v. Sandoz, Inc. et al (D.N.J.) (counsel for Sandoz in BPCIA litigation on patents covering rituximab)
  • Mayne Pharma v. Actavis Elizabeth LLC et al (D. Del.) (counsel for Actavis and Teva in Hatch-Waxman litigation on patents covering doxycycline dosage forms)
  • Sony Corporation v. ARRIS Enterprise LLC (counsel for ARRIS in IPRs concerning broadband technology)
  • Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. et al. (E.D. Tex.) (counsel for Teva in Hatch-Waxman litigation on patents covering mesalamine)
  • Akorn, Inc. v. Senju Pharmaceuticals Co., Ltd. et al. (counsel for Akorn in an IPR and appeal involving a patent claiming a composition of difluprednate)
  • Otsuka Pharmaceuticals Co., Ltd. v. Alembic Pharmaceuticals Limited (D.N.J.) (counsel for Alembic in Hatch-Waxman litigation on patents covering aripiprazole)
  • Salix Pharmaceuticals, Inc. v. Novel Laboratories, Inc. (D. Del.) (counsel for Novel in Hatch-Waxman litigation on patents covering the treatment of ulcerative colitis with mesalamine)

Thought Leadership

Past Events

Contact Information

Phone Number


The George Washington University Law School
Molecular Biology
Coe College


District of Columbia
New York
U.S. Court of Appeals for the Federal Circuit
U.S. District Court for the Eastern District of New York
U.S. District Court for the Southern District of New York
U.S. District Court for the Western District of Michigan
United States Patent & Trademark Office


  • American Intellectual Property Law Association
  • New York Bar Association
  • District of Columbia Bar Association